Cargando…

HOXA5 confers tamoxifen resistance via the PI3K/AKT signaling pathway in ER-positive breast cancer

Tamoxifen is a commonly used drug to treat estrogen receptor-positive patients with breast cancer. Despite the outstanding efficacy of tamoxifen, approximately one-third of patients develop resistance toward it, thereby presenting a therapeutic challenge. HOX genes may be involved in the acquisition...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kim, Clara Yuri, Kim, Yu Cheon, Oh, Ji Hoon, Kim, Myoung Hee
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Ivyspring International Publisher 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8210559/ https://www.ncbi.nlm.nih.gov/pubmed/34149926 http://dx.doi.org/10.7150/jca.59740

Ejemplares similares

The LncRNA HOTAIRM1 Promotes Tamoxifen Resistance by Mediating HOXA1 Expression in ER+ Breast Cancer Cells
por: Kim, Clara Yuri, et al.
Publicado: (2020)

NR4A1 Regulates Tamoxifen Resistance by Suppressing ERK Signaling in ER-Positive Breast Cancer
por: Kim, Yu Cheon, et al.
Publicado: (2021)

Fibronectin expression is upregulated by PI-3K/Akt activation in tamoxifen-resistant breast cancer cells
por: You, Daeun, et al.
Publicado: (2017)

ER-α36, a Variant of ER-α, Promotes Tamoxifen Agonist Action in Endometrial Cancer Cells via the MAPK/ERK and PI3K/Akt Pathways
por: Lin, Sheng-Li, et al.
Publicado: (2010)

Laminar Flow Inhibits ER Stress-Induced Endothelial Apoptosis through PI3K/Akt-Dependent Signaling Pathway
por: Kim, Suji, et al.
Publicado: (2018)

The interaction of the ER with ERBB2 and PI3K results in elevated levels of AKT and p90(RSK )in tamoxifen-resistant MCF-7 cells
por: Pancholi, S, et al.
Publicado: (2005)

Akt1 Decreases Gcn5 Protein Stability through Regulating The Ubiquitin-Proteasome Pathway in Mouse Embryonic Fibroblasts
por: Jeong, Da Som, et al.
Publicado: (2022)

ER and PI3K Pathway Activity in Primary ER Positive Breast Cancer Is Associated with Progression-Free Survival of Metastatic Patients under First-Line Tamoxifen
por: M. Sieuwerts, Anieta, et al.
Publicado: (2020)

Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway
por: Wu, Deng-Pan, et al.
Publicado: (2021)

LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
por: Xue, Xingyang, et al.
Publicado: (2015)

Up-regulation of HOXB cluster genes are epigenetically regulated in tamoxifen-resistant MCF7 breast cancer cells
por: Yang, Seoyeon, et al.
Publicado: (2018)

TNFα Enhances Tamoxifen Sensitivity through Dissociation of ERα-p53-NCOR1 Complexes in ERα-Positive Breast Cancer
por: Kim, Hyunhee, et al.
Publicado: (2021)

Cx43 deficiency confers EMT-mediated tamoxifen resistance to breast cancer via c-Src/PI3K/Akt pathway: Erratum
por: Wu, Deng-Pan, et al.
Publicado: (2022)

Silencing of MicroRNA-21 Confers Radio-Sensitivity through Inhibition of the PI3K/AKT Pathway and Enhancing Autophagy in Malignant Glioma Cell Lines
por: Gwak, Ho-Shin, et al.
Publicado: (2012)

Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer
por: Alves, Carla L., et al.
Publicado: (2023)

HOXA1 Is an Antagonist of ERα in Breast Cancer
por: Belpaire, Magali, et al.
Publicado: (2021)

COPS5 amplification and overexpression confers tamoxifen-resistance in ERα-positive breast cancer by degradation of NCoR
por: Lu, Renquan, et al.
Publicado: (2016)

Metformin enhances tamoxifen-mediated tumor growth inhibition in ER-positive breast carcinoma
por: Ma, Ji, et al.
Publicado: (2014)

Fatty Acid Synthase Confers Tamoxifen Resistance to ER+/HER2+ Breast Cancer
por: Menendez, Javier A., et al.
Publicado: (2021)

HOXA6 inhibits cell proliferation and induces apoptosis by suppressing the PI3K/Akt signaling pathway in clear cell renal cell carcinoma
por: Wu, Feixiang, et al.
Publicado: (2019)

miR-652 Inhibits the Proliferation, Migration, and Invasion of Osteosarcoma Cells by Targeting HOXA9 and Regulating the PI3K/Akt Signaling Pathway
por: Yang, Chao, et al.
Publicado: (2022)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer
por: Liu, Ying, et al.
Publicado: (2020)

PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis
por: Lee, Min-Sik, et al.
Publicado: (2015)

Apoptotic Effects of Xanthium strumarium via PI3K/AKT/mTOR Pathway in Hepatocellular Carcinoma
por: Kim, Juyoung, et al.
Publicado: (2019)

The combination of methylsulfonylmethane and tamoxifen inhibits the Jak2/STAT5b pathway and synergistically inhibits tumor growth and metastasis in ER-positive breast cancer xenografts
por: SP, Nipin, et al.
Publicado: (2015)

Novel PI3K/Akt Inhibitors Screened by the Cytoprotective Function of Human Immunodeficiency Virus Type 1 Tat
por: Kim, Yuri, et al.
Publicado: (2011)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Tamoxifen Action in ER-Negative Breast Cancer
por: Manna, Subrata, et al.
Publicado: (2016)

Blockade of 67-kDa Laminin Receptor Facilitates AQP4 Down-Regulation and BBB Disruption via ERK1/2-and p38 MAPK-Mediated PI3K/AKT Activations
por: Kim, Ji-Eun, et al.
Publicado: (2020)

Fatostatin in Combination with Tamoxifen Induces Synergistic Inhibition in ER-Positive Breast Cancer [Corrigendum]
Publicado: (2022)

A retrospective cohort study of tamoxifen versus surgical treatment for ER-positive gynecomastia
por: He, Weili, et al.
Publicado: (2023)

FGFR1 Is Associated With Tamoxifen Resistance and Poor Prognosis of ER-Positive Breast Cancers by Suppressing ER Protein Expression
por: Lv, Qing, et al.
Publicado: (2021)

Cystatin SN Affects Cell Proliferation by Regulating the ERα/PI3K/AKT/ERα Loopback Pathway in Breast Cancer
por: Liu, Yanfang, et al.
Publicado: (2019)

Tumor‐associated macrophages secrete CC‐chemokine ligand 2 and induce tamoxifen resistance by activating PI3K/Akt/mTOR in breast cancer
por: Li, Dongbo, et al.
Publicado: (2019)

δEF1 Down-Regulates ER-α Expression and Confers Tamoxifen Resistance in Breast Cancer
por: Guo, Shaocong, et al.
Publicado: (2012)

Overexpression of BQ323636.1 Modulated AR/IL-8/CXCR1 Axis to Confer Tamoxifen Resistance in ER-Positive Breast Cancer
por: Tsoi, Ho, et al.
Publicado: (2022)

Dysregulation of PI3K/Akt/PTEN Pathway in Canine Mammary Tumor
por: Kim, Soo-Hyeon, et al.
Publicado: (2021)

Spatholobus suberectus Column Extract Inhibits Estrogen Receptor Positive Breast Cancer via Suppressing ER MAPK PI3K/AKT Pathway
por: Sun, Jia-Qi, et al.
Publicado: (2016)

Disruption of the ER-α36-EGFR/HER2 Positive Regulatory Loops Restores Tamoxifen Sensitivity in Tamoxifen Resistance Breast Cancer Cells
por: Yin, Li, et al.
Publicado: (2014)

Inhibition of Dickkopf-1 enhances the anti-tumor efficacy of sorafenib via inhibition of the PI3K/Akt and Wnt/β-catenin pathways in hepatocellular carcinoma
por: Seo, Sang Hyun, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_iomftji9qb7egrggnkn7bidpdb